Compositions and methods for enhancing musculoskeletal effects of one or more anabolic amino acids on bone health

By using compositions of anabolic amino acids and autophagy-induced compounds in critically ill individuals, the autophagy process is promoted, the problems of bone loss and muscle mass are solved, and bone strength and mineral density are improved, and the Risk and mortality of related diseases.

CN118900686APending Publication Date: 2024-11-05SOCIETE DES PRODUITS NESTLE SA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380023856.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-03
Filing Date
2023-02-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

Critical patients and older individuals face serious challenges in bone loss, muscle mass reduction and loss of function, existing treatments increase the risk of organ failure and death, and lack effective nutritional support measures.

Method used

Using a composition containing an anabolic amino acid and autophagy-induced compounds, the autophagy process is enhanced by promoting protein synthesis and removal of damaged cellular substances, thereby improving skeletal muscle effect and bone health.

Benefits of technology

Effectively offset the negative effects of anabolic amino acids on autophagy, enhance bone mass, bone strength and bone mineral density, reduce the incidence and mortality caused by excessive catabolism, reverse multi-organ dysfunction syndrome, prevent or treat bone quality Bone diseases such as porridge.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005012135860000011
    Figure HDA0005012135860000011
  • Figure HDA0005012135860000021
    Figure HDA0005012135860000021
Patent Text Reader

Abstract

A method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mass, and bone mineral density in a subject in need thereof, the method comprising administering to the subject a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy inducing compounds. In one embodiment, one or more autophagy-inducing compounds are selected from thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B, or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5 'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., beta-hydroxybutyrate, ketones salt or ketones ester derivatives), 4, 4'-dihydroxy-4, 4 '-dihydroxy-4, 4'-dihydroxy-4, 4 '-dihydroxy-4, 4'-dihydroxy-4, 4 '-dihydroxy-4, 4'-dihydroxy-4, 4 '-dihydroxy-4, 4'-dihydroxy-4, 4 '-dihydroxy-4, 4' The invention relates to 4, 4 '-dimethoxychalcone and mixtures thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Background Art

[0001] The present disclosure generally relates to compositions and methods for improving and / or enhancing at least one of bone mineralization, bone strength, bone mass and bone mineral density in an individual by administering a composition comprising one or more anabolic amino acids and one or more autophagy inducing compounds to an individual in need thereof. More specifically, the present disclosure relates to administering a composition comprising one or more anabolic amino acids, the composition also comprising one or more autophagy inducing compounds, the amount of which effectively makes the composition at least neutral for autophagy and preferably positive for autophagy, despite any negative effect of one or more anabolic amino acids on autophagy. The composition can simultaneously promote protein synthesis and the removal of damaged cellular material. The recipients of administration can be: critically ill patients, such as patients in an intensive care unit (ICU); elderly patients, such as elderly individuals; patients with bone disease or suffering from bone loss; patients with sarcopenia or weakness; or individuals with chronic kidney disease (e.g., amino acid loss caused by dialysis) and / or acute renal injury.

[0002] Due to major advances in intensive care medicine, critically ill patients often survive acute conditions that were once fatal. However, among these patients who survive this initial phase and enter the chronic phase of serious illness, mortality remains high. Mortality is usually due to unresolved multiple organ failure, acute kidney injury and failure, critical illness myopathy, or less severe forms of myasthenia. Treatments have been introduced to improve muscle myopathy and myasthenia, such as intravenous infusion of nutritional solutions, growth hormone, or androgens, but have failed because these interventions unexpectedly increase the risk of organ failure and death. In addition, nutritional support for trauma and surgical patients may actually have adverse effects.

[0003] Effective measures to provide appropriate treatment and adequate nutrition to critically ill patients are still lacking.

[0004] In addition, age-related muscle loss, bone mineral density loss, bone mass and function loss are inevitable in all individuals; however, its progression depends mainly on genetic and environmental factors, such as physical activity and nutritional intake. Sarcopenia has been defined as a point at which age-related muscle mass loss and function loss make patients weak and affect quality of life. In contrast, frailty is another classification of age-related physical function decline, characterized by low muscle strength and low muscle function rather than muscle mass. Sarcopenia is clinically defined based on low muscle mass and low muscle function using cutoff values ​​that classify the elderly population for individuals in pathologically active states. Sarcopenia predicts future disability and death and was designated as an official ICD-10 disease code in 2016 (Anker et al., 2016).

[0005] There is a need in the art for compositions comprising anabolic amino acids and autophagy inducers and methods of using such compositions to increase or maintain musculoskeletal effects, bone benefits (eg, synergistic effects on bone strength and additive effects on bone mass). Summary of the invention

[0006] The degradation of cytoplasmic proteins is mediated by a cellular process called macroautophagy (also referred to as autophagy). The autophagic process is also involved in inflammatory responses and promotes immune system destruction of bacteria. Autophagy constitutes the main lysosomal degradation pathway, resulting in the recycling of impaired and potentially harmful cellular materials, such as damaged mitochondria. It is worth noting that autophagy counteracts cell death and extends lifespan in various aging models.

[0007] As described in detail later herein, the inventors have found that some amino acids (e.g., arginine, glutamine, and leucine) and / or anabolic branched-chain amino acids (e.g., leucine and isoleucine) known to participate in musculoskeletal anabolism through the mTOR pathway reduce basal autophagy. However, the inventors have found that autophagy-inducing compounds (such as thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B, or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts or ketone ester derivatives), 4,4'-dimethoxychalcone, and mixtures thereof) can strongly induce autophagy, and thus can counteract any negative effects of anabolic amino acids on autophagy, including bone mass loss and loss of function, muscle and neuromuscular degeneration, and muscle mass loss and loss of function.

[0008] On the other hand, as detailed in experimental data shown later herein, the inventors found that some amino acids (e.g., arginine, glutamine, and leucine) and / or anabolic branched-chain amino acids (e.g., leucine and isoleucine) known to participate in musculoskeletal anabolism through the mTOR pathway reduced basal autophagy. However, the inventors surprisingly found that some autophagy inducers (such as thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B, or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts, or ketone ester derivatives), or 4,4'-dimethoxychalcone) can strongly induce autophagy, and thus can offset any negative effects of anabolic amino acids on autophagy, including bone degeneration and bone mass loss and strength loss.

[0009] Thus, in general embodiments, the present disclosure provides a method of enhancing the musculoskeletal and bone effects of one or more anabolic amino acids in an individual in need thereof. The method comprises administering to the individual a composition comprising one or more anabolic amino acids, the composition further comprising one or more autophagy inducing compounds, the total amount of the autophagy inducing compounds being effective to render the composition at least neutral for autophagy and preferably positive for autophagy.

[0010] In one aspect, the present disclosure provides a method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mineral density, and bone mass in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy inducers or their precursors.

[0011] In one embodiment, the one or more anabolic amino acids are selected from leucine, isoleucine, arginine, glutamine, citrulline and mixtures thereof. The one or more anabolic amino acids may be present in an amount effective to activate mTOR in an individual including at least one of leucine, glutamine or arginine.

[0012] In one embodiment, the one or more autophagy inducing compounds are selected from thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts or ketone ester derivatives), 4,4'-dimethoxychalcone, and mixtures thereof.

[0013] In one embodiment, the composition induces autophagy in skeletal muscle.

[0014] In one embodiment, the composition induces autophagy in bone cells.

[0015] In one embodiment, the subject is an elderly subject.

[0016] In one embodiment, the subject has or is at risk of developing sarcopenia or frailty.

[0017] In one embodiment, the subject is critically ill.

[0018] In one embodiment, the subject has or is at risk of developing critical illness myopathy.

[0019] In one embodiment, the subject has a serious illness manifesting as acute renal failure or is at risk of developing acute renal failure.

[0020] In one embodiment, the subject has chronic kidney disease with or without associated loss of bone mass or strength.

[0021] In one embodiment, the subject suffers from a bone disease.

[0022] In one embodiment, the subject has a condition selected from osteoporosis, osteomalacia (adults), and conditions of low bone mineral density or quality (such as fathering growth in children), osteitis fibrosa cystica, Paget's disease of bone, and pyramiding (turtles).

[0023] In one embodiment, the composition comprises a protein providing at least a portion of one or more anabolic amino acids and / or at least a portion of one or more autophagy inducing compounds, the protein being selected from (i) a protein from an animal source, (ii) a protein from a plant source, and (iii) a mixture thereof, preferably one or more of (a) milk protein, (b) whey protein, (c) caseinate, (d) micellar casein, (e) pea protein, (f) soy protein, and (g) a mixture thereof. In a specific non-limiting example, at least a portion of the protein is collagen, i.e., unhydrolyzed and / or hydrolyzed collagen.

[0024] The protein can be selected from (i) amino acids in free form, (ii) unhydrolyzed proteins, (iii) partially hydrolyzed proteins, (iv) fully hydrolyzed proteins, and (v) mixtures thereof. For example, partially hydrolyzed proteins can include unhydrolyzed proteins, amino acids, peptides, and polypeptides. Fully hydrolyzed proteins can include amino acids, peptides, and polypeptides. In one embodiment, partially hydrolyzed proteins or fully hydrolyzed proteins can include peptides having a length of 2 to 10 amino acids. Optionally, at least a portion of the protein is hydrolyzed. For example, 5% to 95% of the protein can be hydrolyzed. Optionally, the protein has a formula selected from the following: (i) at least 50% of the protein has a molecular weight of 1 kDa to 5 kDa, (ii) at least 50% of the protein has a molecular weight of 5 kDa to 10 kDa, and (iii) at least 50% of the protein has a molecular weight of 10 kDa to 20 kDa.

[0025] In one embodiment, the composition comprises a carbohydrate source and / or a fat source.

[0026] In one embodiment, administration is by at least one route selected from oral, enteral, parenteral, and intravenous injection.

[0027] In one embodiment, the total amount of the one or more anabolic amino acids is about equal to or greater than the total amount of the one or more anabolic amino acids in the composition.

[0028] In another embodiment, the present disclosure provides a composition comprising one or more anabolic amino acids, the composition further comprising one or more autophagy inducing compounds, the total amount of which is effective to make the composition at least neutral for autophagy and preferably positive for autophagy. The composition can be selected from food compositions, dietary supplements, nutritional compositions, nutritional medicines, powdered nutritional products reconstituted with water or milk before consumption, food additives, drugs, beverages, and combinations thereof.

[0029] One or more embodiments provided by the present disclosure provide an advantage of improving a condition in a critically ill animal, critically ill human, elderly animal, or elderly human.

[0030] Another advantage of one or more embodiments provided by the present disclosure is the prevention or treatment of excessive catabolism, for example, in critically ill patients or elderly individuals.

[0031] Yet another advantage of one or more embodiments provided by the present disclosure is the reduction or prevention of the risk of morbidity or mortality due to excessive catabolism, for example, in critically ill patients or elderly individuals.

[0032] Another advantage of the present disclosure is to reverse, treat or cure multiple organ dysfunction syndrome in critically ill patients.

[0033] Another advantage of the present disclosure is to prevent or treat bone loss in an individual in need thereof, maintain bone health in an individual in need thereof, enhance or improve bone mineralization in an individual in need thereof, enhance or improve bone strength in an individual in need thereof, enhance or improve bone mineral density in an individual in need thereof, and / or enhance or improve bone mass in an individual in need thereof.

[0034] Another advantage of the present disclosure is the prevention or treatment of a bone disorder selected from the group consisting of osteoporosis, osteomalacia (adults), conditions of low bone mineral density or quality (such as growth and development in children), osteitis fibrosa cystica, Paget's disease of bone, and pyramidal (turtle) disease.

[0035] On the other hand, as detailed in experimental data shown later herein, the inventors have found that some amino acids (e.g., arginine, glutamine, and leucine) and / or anabolic branched-chain amino acids (e.g., leucine and isoleucine) known to participate in musculoskeletal anabolism via the mTOR pathway reduce basal autophagy. However, the inventors have surprisingly found that some autophagy inducers (such as thymol and / or some amino acids, such as glycine, cysteine, proline, glutamic acid, valine, tyrosine, or their precursors such as serine (as a precursor of glycine), N-acetylcysteine, and methionine (as a precursor of cysteine)) can strongly induce autophagy, and therefore can offset any negative effects of anabolic amino acids on autophagy, including bone degeneration and loss of bone mass and strength.

[0036] Thus, in a general embodiment, the present disclosure provides a method of enhancing the musculoskeletal and bone effects of one or more anabolic amino acids in an individual in need thereof. The method comprises administering to the individual a composition comprising one or more anabolic amino acids, the composition further comprising one or more autophagy inducers and / or one or more autophagy inducing amino acids or their precursors, the total amount of these autophagy inducers and / or autophagy inducing amino acids or their precursors being effective to render the composition at least neutral for autophagy and preferably positive for autophagy.

[0037] In one embodiment, the one or more anabolic amino acids are selected from leucine, isoleucine, arginine, glutamine, citrulline, lysine and mixtures thereof. The one or more anabolic amino acids may be present in an amount effective to activate mTOR in an individual including at least one of leucine, glutamine or arginine.

[0038] In one embodiment, the one or more autophagy inducers comprises thymol.

[0039] In one embodiment, the one or more autophagy inducing amino acids are selected from glycine, cysteine, proline, glutamic acid, valine, tyrosine or precursors thereof and mixtures thereof.

[0040] In one embodiment, the composition induces autophagy in bone.

[0041] In one embodiment, the composition induces autophagy in bone cells.

[0042] In one embodiment, the subject is an elderly subject.

[0043] In one embodiment, the subject is critically ill.

[0044] In one embodiment, the subject has or is at risk of developing critical illness myopathy.

[0045] In one embodiment, the subject has a serious illness manifesting as acute renal failure or is at risk of developing acute renal failure.

[0046] In one embodiment, the subject has chronic kidney disease with or without associated loss of bone mass or strength.

[0047] In one embodiment, the subject suffers from a bone disease.

[0048] In one embodiment, the subject has a disorder selected from the group consisting of osteoporosis, osteomalacia (in adults) and rickets (in children), osteitis fibrosa cystica, Paget's disease of bone, and pyramidal (turtle) disease.

[0049] In one embodiment, the composition comprises a protein providing at least a portion of one or more anabolic amino acids and / or at least a portion of one or more autophagy inducers and / or at least a portion of one or more autophagy inducing amino acids or their precursors, the protein being selected from (i) a protein from an animal source, (ii) a protein from a plant source, and (iii) a mixture thereof, preferably one or more of (a) milk protein, (b) whey protein, (c) caseinate, (d) micellar casein, (e) pea protein, (f) soy protein, and (g) a mixture thereof. In a specific non-limiting example, at least a portion of the protein is collagen, i.e., unhydrolyzed and / or hydrolyzed collagen.

[0050] The protein may be selected from (i) free amino acids, (ii) unhydrolyzed proteins, (iii) partially hydrolyzed proteins, (iv) fully hydrolyzed proteins, and (v) mixtures thereof. The protein may comprise peptides of 2 to 10 amino acids in length. Optionally, at least a portion of the protein is 5% to 95% hydrolyzed. Optionally, the protein has a formulation selected from the following: (i) at least 50% of the protein has a molecular weight of 1 kDa to 5 kDa, (ii) at least 50% of the protein has a molecular weight of 5 kDa to 10 kDa, and (iii) at least 50% of the protein has a molecular weight of 10 kDa to 20 kDa.

[0051] In one embodiment, the composition comprises a carbohydrate source and / or a fat source.

[0052] In one embodiment, administration is by at least one route selected from oral, enteral, parenteral, and intravenous injection.

[0053] In one embodiment, the total amount of the one or more anabolic amino acids is about equal to or greater than the total amount of the one or more anabolic amino acids in the composition.

[0054] In another embodiment, the present disclosure provides a composition comprising one or more anabolic amino acids, the composition further comprising one or more autophagy inducing amino acids or their precursors, the total amount of these autophagy inducing amino acids or their precursors being effective to make the composition at least neutral for autophagy and preferably positive for autophagy. The composition can be selected from food compositions, dietary supplements, nutritional compositions, nutritional medicines, powdered nutritional products reconstituted with water or milk before consumption, food additives, drugs, beverages, and combinations thereof.

[0055] One or more embodiments provided by the present disclosure provide an advantage of improving conditions in a critically ill animal, critically ill human, elderly animal, or elderly human.

[0056] Another advantage of one or more embodiments provided by the present disclosure is the prevention or treatment of excessive catabolism, for example, in critically ill patients or elderly individuals.

[0057] Yet another advantage of one or more embodiments provided by the present disclosure is the reduction or prevention of the risk of morbidity or mortality due to excessive catabolism in, for example, critically ill patients or elderly individuals.

[0058] Another advantage of the present disclosure is to reverse, treat or cure multiple organ dysfunction syndrome in critically ill patients.

[0059] Another advantage of the present disclosure is to prevent or treat bone loss in an individual in need thereof, maintain bone health in an individual in need thereof, enhance or improve bone mineralization in an individual in need thereof, enhance or improve bone strength in an individual in need thereof, enhance or improve bone mineral density in an individual in need thereof, and / or enhance or improve bone mass in an individual in need thereof.

[0060] Another advantage of the present disclosure is the prevention or treatment of a bone disease selected from the group consisting of osteoporosis, osteomalacia (adults) and rickets (children), osteitis fibrosa cystica, Paget's disease of bone and pyramidal (turtle) disease.

[0061] In yet another aspect, the present disclosure provides a method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mineral density, and bone mass in an individual in need thereof, the method comprising administering to the individual a composition comprising anabolic amino acids, and the composition further comprising an autophagy inducer or a precursor thereof.

[0062] In one embodiment, the autophagy inducer comprises thymol.

[0063] In one embodiment, the autophagy inducing agent comprises an autophagy inducing amino acid.

[0064] In one embodiment, the autophagy inducing amino acid is selected from the group consisting of glycine, cysteine, proline, glutamic acid, valine, tyrosine, their precursors and mixtures thereof.

[0065] In one embodiment, the precursor is selected from the group consisting of serine, N-acetylcysteine ​​(NAC), methionine, and mixtures thereof.

[0066] In one embodiment, the one or more anabolic amino acids are selected from the group consisting of leucine, isoleucine, arginine, glutamine, citrulline, and mixtures thereof.

[0067] In one embodiment, the anabolic amino acid is selected from the group consisting of leucine, arginine, glutamine, and mixtures thereof, and the composition is administered in an amount effective to activate mTOR in the individual.

[0068] In one embodiment, the composition is administered in an amount effective to induce autophagy in bone.

[0069] In one embodiment, the subject is an elderly subject.

[0070] In one embodiment, the subject suffers from a bone disease.

[0071] In one embodiment, the subject has a disorder selected from the group consisting of osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone, pyramidal disease, and combinations thereof.

[0072] In one embodiment, the composition comprises a protein that provides at least a portion of the anabolic amino acids and / or at least a portion of the autophagy inducer or a precursor thereof, wherein at least a portion of the protein is selected from a protein from an animal source, a protein from a plant source, and a mixture thereof.

[0073] In one embodiment, the composition comprises a protein selected from the group consisting of milk protein, whey protein, caseinate, micellar casein, pea protein, soy protein, and mixtures thereof.

[0074] In one embodiment, the composition comprises a component selected from the group consisting of amino acids in free form, unhydrolyzed proteins, partially hydrolyzed proteins, fully hydrolyzed proteins, and mixtures thereof.

[0075] In one embodiment, at least a portion of the protein is hydrolyzed.

[0076] In one embodiment, the composition comprises at least partially hydrolyzed protein comprising peptides having from 2 to 10 amino acids.

[0077] In one embodiment, the protein has a formula selected from the following: (i) proteins of which at least 50% of the protein has a molecular weight between 1 kDa and 5 kDa, (ii) proteins of which at least 50% of the protein has a molecular weight between 5 kDa and 10 kDa, and (iii) proteins of which at least 50% of the protein has a molecular weight between 10 kDa and 20 kDa.

[0078] In one embodiment, the composition further comprises a carbohydrate source and / or a fat source.

[0079] In one embodiment, the composition is administered by at least one route selected from oral, enteral, parenteral, and intravenous injection.

[0080] In one embodiment, the composition comprises an anabolic amino acid in an amount about equal to or greater than the amount of anabolic amino acid.

[0081] Additional features and advantages are described herein, and will be apparent from the following detailed description and accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0082] Figure 1 is a graph showing exemplary autophagy activation by various amino acids in the experimental examples disclosed herein. Figure 1 As shown, amino acids (such as glycine, cysteine, proline, glutamic acid, valine, tyrosine, arginine, asparagine and phenylalanine) all show at least some autophagy activating effect. Preferably, glycine, cysteine, proline, glutamic acid, valine and tyrosine all show autophagy activating effect.

[0083] Figure 2 is a set of graphs showing another exemplary activation of autophagy by various amino acids in the experimental examples disclosed herein. Figure 2 As shown, cysteine, glycine, and valine all exhibited autophagy-activating effects, whereas leucine did not exhibit any autophagy-activating effect.

[0084] Fig. 3 is a set of diagrams showing yet another exemplary autophagy activation by various amino acids in the experimental examples disclosed herein. As shown in Fig. 3, proline and glutamate show obvious autophagy activation effects, while arginine shows a smaller autophagy activation effect compared to proline and glutamate.

[0085] Figure 4 shows the effect of a specific amino acid mixture (AA) on the force-frequency response of aged rats (Old) and a comparison with adult mice fed a normal diet. Rats at 20 months of age were fed a control diet or the same diet supplemented with specific amino acids for 3 months. Adult mice at 6 months of age were fed a control diet for 3 months. Results are expressed as mean ± standard error of the mean. Adult: 6 month old mice, fed a control diet. Old: 20 month old, fed a control diet. Old+AA: 20 month old, fed a control diet supplemented with a specific amino acid mixture.

[0086] 5 shows the results of evaluating the long-term (3 month) effects of thymol (an exemplary autophagy inducer) and an amino acid mixture (referred to as an autophagy inducer), alone or in combination, on bone health (bone mass and / or bone strength) in aged mice.

[0087] 6 is a set of graphs showing the additive effect of the combination of thymol and an amino acid mixture (AA) on bone mass ( FIG. 6 a ) and the synergistic effect of the combination of thymol and an amino acid mixture (AA) on bone strength ( FIG. 6 b ). DETAILED DESCRIPTION

[0088] definition

[0089] Some definitions are provided below. However, definitions may be located in the "Implementation" section below, and the above heading "Definitions" does not indicate that such disclosure in the "Implementation" section is not a definition.

[0090] All percentages are by weight based on the total weight of the composition, unless otherwise indicated. Similarly, all amounts and all ratios are by weight, unless otherwise indicated. When pH is mentioned, the value corresponds to the pH measured at 25° C. using standard equipment. As used herein, “about”, “approximately” and “substantially” are understood to refer to a number within a certain numerical range, such as within the range of -10% to +10% of the mentioned number, preferably -5% to +5% of the mentioned number, more preferably -1% to +1% of the mentioned number, and most preferably -0.1% to +0.1% of the mentioned number.

[0091] In addition, all numerical ranges herein should be understood to include all integers or fractions within the range. In addition, these numerical ranges should be understood to provide support for claims involving any number or subset of numbers within the range. For example, the disclosure of 1 to 10 should be understood to support ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.

[0092] As used herein and in the appended claims, unless the context clearly dictates otherwise, the singular form of a word includes the plural form. Thus, references to "one," "an," and "the" generally include the plural form of the corresponding term. For example, references to "an amino acid" or "the amino acid" include a plurality of such "amino acids." The term "and / or" employed in the context of "X and / or Y" should be interpreted as "X" or "Y" or "X and Y." Similarly, "at least one of X or Y" should be interpreted as "X" or "Y" or "both X and Y."

[0093] Similarly, the words "include / comprise / contain" are all intended to be interpreted inclusively rather than exclusively. Likewise, the terms "include / comprise" and "or" should be considered inclusive unless the context clearly prohibits such an interpretation. However, the embodiments provided by the present disclosure may not contain any elements that are not explicitly disclosed herein. Therefore, the disclosure of an embodiment defined by the terms "include / comprise / contain" is also the disclosure of multiple embodiments of "consisting essentially of the disclosed components" and "consisting of the disclosed components."

[0094] The term "exemplary" used herein (especially when followed by a list of terms) is used for illustration only and should not be considered exclusive or comprehensive. Any embodiment disclosed herein may be combined with any other embodiment disclosed herein, unless otherwise explicitly indicated.

[0095] "Animal" includes, but is not limited to, mammals, including, but not limited to, rodents; aquatic mammals; domestic animals, such as dogs and cats; farm animals, such as sheep, pigs, cattle and horses; and humans. When "animal," "mammal," or their plural forms are used, these terms also apply to any animal that is capable of having the effects expressed or intended to be expressed by the context of the paragraph, such as an animal capable of autophagy. As used herein, the term "patient" should be understood to include animals, such as mammals, and preferably humans, that receive or intend to receive treatment as defined herein. Although the terms "individual" and "patient" are commonly used herein to refer to humans, the present disclosure is not limited thereto.

[0096] Thus, the terms "subject" and "patient" refer to any animal, mammal or human that can benefit from the methods and compositions disclosed herein. In fact, non-human animals experience long-term critical illness similar to human conditions. These critical animals experience the same metabolic, immune and endocrine disruptions as their human counterparts, as well as the development of organ failure, bone loss and muscle wasting. In addition, animals also experience the effects of aging.

[0097] In the case of humans, the term "elderly" refers to an age of at least 55 years, preferably over 63 years, more preferably over 65 years, and most preferably over 70 years, since birth. In the context of humans, the term "elderly" or "elderly individual" refers to an age of at least 45 years, preferably over 50 years, more preferably over 55 years, since birth, and includes elderly individuals.

[0098] For other animals, "middle aged and old" or "senile individuals" are those that have exceeded 50% of the average life span for their particular species and / or breed within a species. An animal is considered "senile" if it exceeds 66% of the average life expectancy, preferably exceeds 75% of the average life expectancy, and more preferably exceeds 80% of the average life expectancy. A senile cat or dog is at least about 5 years old since birth. A geriatric cat or dog is at least about 7 years old since birth.

[0099] "Sarcopenia" is defined as the age-related loss of muscle mass and function, including muscle strength and walking speed. Sarcopenia can be characterized by one or more of low muscle mass, low muscle strength, and low physical fitness.

[0100] Low muscle mass may be generally based on low limb lean mass (ALM index) normalized to the square of height, specifically an ALM index of less than 7.00 kg / m2 for men and less than 5.40 kg / m2 for women. Low physical performance may be generally based on walking speed, specifically a walking speed of less than 0.8 m / sec. Low muscle strength may be generally based on low grip strength, specifically a grip strength of less than 26 kg for men and less than 18 kg for women.

[0101] Additionally or alternatively, sarcopenia in a subject may be diagnosed based on the definition of EWGSOP (European Working Group on Sarcopenia in Older People), for example as described by Crutz-Jentoft et al. in 2010. Low muscle mass can generally be based on low limb lean body mass (ALM index) normalized to the square of height, specifically an ALM index of less than 7.23 kg / m for men. 2 , and the ALM index of women is less than 5.67kg / m 2 Low physical performance may be generally based on walking speed, specifically a walking speed of less than 0.8 m / sec. Low muscle strength may be generally based on low grip strength, specifically a grip strength of less than 30 kg for males and less than 20 kg for females.

[0102] Additionally or alternatively, sarcopenia in a subject may be diagnosed based on the definition of the Foundation for the National Institutes of Health (FNIH), e.g., as described in Studenski et al., 2014. Low muscle mass may generally be based on low limb lean mass (ALM) normalized to body mass index (BMI; Kg / m2), specifically a ratio of ALM to BMI of less than 0.789 for males and less than 0.512 for females. Low physical performance may generally be based on walking speed, specifically a walking speed of less than 0.8 m / sec. Low muscle strength may generally be based on low grip strength, specifically a grip strength of less than 26 kg for males and less than 16 kg for females. Low muscle strength may also generally be based on a low grip strength: body mass index, specifically a grip strength: body mass index of less than 1.00 for males and less than 0.56 for females.

[0103] As used herein, “frailty” is defined as a clinically recognizable state of increased vulnerability resulting from aging-related declines in reserve and function across multiple physiological systems, which impairs the ability to cope with daily or acute stressors. In the absence of definitive quantitative criteria, Fried et al operationally defined frailty as meeting three of five phenotypic criteria indicating impaired energy: (1) weakness (handgrip strength in the bottom 20% of the baseline population, adjusted for sex and body mass index), (2) poor endurance and energy (self-reported exertion versus energy expenditure), and (3) poor maxima), (3) slowness (bottom 20% of the baseline population, based on time to walk 15 feet, adjusted for sex and standing height), (4) low physical activity (weighted fraction of kilocalories consumed per week at baseline, lowest quintile of physical activity determined for each sex; e.g., less than 383 kcal / week for men and less than 270 kcal / week for women), and / or unintentional weight loss (less than 10 pounds in the past year). Fried LP, Tangen CM, Walston J, et al., "Frailty in older adults: evidence for a phenotype." J. Gerontol. Biol. Sci. Med. Sci. 56(3):M146–M156 (2001). The presence of one or both of these criteria identifies the pre-frail stage as being at high risk for progression to frailty.

[0104] "Cachexia" is a complex metabolic syndrome associated with an underlying disease and is characterized by muscle loss with or without loss of fat mass. The prominent clinical features of cachexia are weight loss in adults (corrected for fluid retention) or growth failure in children (excluding endocrine disorders).

[0105] Cachexia often occurs in patients with conditions such as cancer, chronic heart failure, renal failure, chronic obstructive pulmonary disease, AIDS, autoimmune disorders, chronic inflammatory disorders, cirrhosis, anorexia, chronic pancreatitis and / or metabolic acidosis and neurodegenerative diseases.

[0106] There are certain types of cancer in which cachexia is particularly prevalent, such as pancreatic, esophageal, stomach, intestinal, lung and / or liver cancer.

[0107] The internationally recognized diagnostic criteria for cachexia are based on current weight and height (body mass index [BMI] < 20 kg / m 2 ) or skeletal muscle mass (measured by DXA, MRI, CT or bioimpedance), greater than 5% body weight loss in a limited time, such as 6 months, or greater than 2% body weight loss in individuals who have shown depletion. Cachexia can develop gradually in various stages, i.e., pre-cachexia develops into cachexia, and then develops into refractory cachexia. The severity can be classified according to the degree of depletion of energy stores and body protein (BMI) combined with the degree of sustained weight loss.

[0108] Specifically, cancer cachexia has been defined as a body weight loss of >5% in the past 6 months (without simple starvation); or a BMI <20 and any degree of body weight loss >2%; or a limb lean body mass consistent with low muscle mass (<7 26 kg / m in men). 2 ; Women <5 45 kg / m 2 ) and any weight loss >2% (Fearon et al., 2011).

[0109] "Pre-cachexia" can be defined as a loss of ≤5% of weight loss along with anorexia and metabolic changes. Currently, there are no robust biomarkers to identify those pre-cachexia patients who are likely to progress further or the rate at which they will progress further. Refractory cachexia is defined essentially based on the patient's clinical characteristics and circumstances.

[0110] The term "treat" includes any effect that results in an improvement in a condition or disorder, such as alleviation, reduction, regulation, or elimination of the condition or disorder. The term does not necessarily mean that the subject is treated until full recovery. Non-limiting examples of "treating" a condition or disorder include: (1) inhibiting the condition or disorder, i.e., preventing the development of the condition or disorder or its clinical symptoms, and (2) alleviating the condition or disorder, i.e., causing the condition or disorder or its clinical symptoms to temporarily or permanently subside. Treatment can be patient-related or physician-related.

[0111] The term "preventing" means causing clinical symptoms of the referenced condition or disorder not to develop in an individual who may be exposed to or susceptible to the condition or disorder but does not yet experience or display symptoms of the condition or disorder. The terms "condition" and "disorder" mean any disease, condition, symptom, or indication.

[0112] The relative terms "improved," "increased," "enhanced," and the like refer to the effect of a composition comprising both one or more anabolic amino acids and one or more autophagy inducing compounds relative to a composition that does not contain the one or more autophagy inducing compounds or has less of the one or more autophagy inducing compounds but is otherwise the same.

[0113] As used herein, the term "autophagy" refers to a catabolic cellular mechanism involving the cellular degradation of unnecessary or dysfunctional cellular components (such as intracellular proteins, protein aggregates, organelles, cell membranes, organelle membranes, and other cellular components) through the action of lysosomes. The mechanism of autophagy can include: (i) the formation of a membrane around a targeted area of ​​the cell, separating the contents from the rest of the cytoplasm, (ii) the fusion of the resulting vesicles with lysosomes or endosomes and subsequent degradation of the vesicle contents. The term autophagy can also refer to one of the following mechanisms by which starving cells reallocate nutrients from less unnecessary processes to more important processes.

[0114] In one embodiment, autophagy is a survival pathway in which non-functional proteins and organelles are degraded in lysosomes for recycling and energy production. For example, in vitro and animal and human studies have shown that autophagy dysfunction in osteocytes is associated with the onset of bone diseases (such as osteoporosis). Autophagy has been identified as a key player in the onset and progression of physiological processes and bone-related diseases (Pierrefite-Carle, V., Santucci-Darmanin, S., Breuil, V., Camuzard, O. & Carle, GF Autophagy in bone: self-eating to stay inbalance. Ageing Res Rev. 24 (Pt B), 206–217 (2015)). Autophagy controls the energy and chemical homeostasis of each single cell and various tissue types (including bone) (Smith, M. & Wilkinson, S. ER homeostasis and autophagy. Essays Biochem. 61, 625–635 (2017)).

[0115] As used herein, the term "bone disease" refers to any bone-related disease or any metabolic bone disorder. For example, metabolic bone disorders may include osteoporosis, osteomalacia (adults) and conditions with low bone mineral density or quality (such as growth and development in children), osteitis fibrosa cystica, Paget's disease of bone, pyramidal (turtle) disease, renal osteodystrophy, etc.

[0116] As used herein, the term "bone loss" refers to any loss of bone mass due to a condition in which bone turnover is abnormally increased, for example, due to osteoporosis (including postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and juvenile osteoporosis); osteopenia; hormonal deficiency (vitamin D deficiency, tnalc, and female hypogonadism); hormonal excess (hyperprolactinemia, excess glucocorticoids, hyperthyroidism, hyperparathyroidism); nutritional factors ( digestive disorders, malabsorption syndromes); Paget's disease; other forms of bone loss due to drug therapy; osteoarthritis; renal bone disease; inflammatory disorders (Crohn's disease, rheumatoid arthritis); immobility; space travel; osteoporosis due to tumor bone marrow disorders; osteogenesis imperfecta; hypoalkaline phosphatasia; osteoporosis after hormone replacement therapy and genetic disorders and inborn errors of metabolism that lead to bone brittleness (familial hypoalkaline phosphatasia, Gaucher's disease, osteogenesis imperfecta, collagen disorders).Other diseases and conditions that may be treated by the combinations of the present invention include: achondroplasia, cleidocranial osteodysplasia, enchondromatosis, fibrodysplasia, hypophosphatemic rickets, Marfan syndrome, multiple hereditary exometastasis, neurofibromatosis, osteosclerosis, osteopoikilosis, sclerosis, fractures, periodontal disease, pseudoarthrosis, pyogenic osteomyelitis, periodontal disease, antiepileptic drug-induced bone loss, primary and secondary, renal osteodystrophy, bone permeability disorders, oral bone loss, jaw bone loss. Osteonecrosis, juvenile Paget's disease, wax tear bone disease, metabolic bone disease, mastocytosis, sickle cell anemia / disease, organ transplant-related bone loss, renal transplant-related bone loss, systemic lupus erythematosus, ankylosing spondylitis, epilepsy, juvenile arthritis, thalassemia, mucopolysaccharidoses, Fabry disease, Turner syndrome, Down syndrome, Klinefelter syndrome, leprosy, Perth disease, juvenile idiopathic scoliosis, infantile multisystem inflammatory disease, Winchester syndrome, Menkes disease, Wilson disease, ischemic bone disease (such as Legg-Calve-Perthes disease, regional migratory osteoporosis), anemic states, heparin-induced bone loss, bone marrow disorders, scurvy, malnutrition, calcium deficiency, idiopathic osteopenia, osteoporosis, congenital osteopenia or osteoporosis, alcoholic liver disease, postmenopausal state, chronic inflammatory diseases, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, inflammatory colitis, oligomenorrhea, amenorrhea, pregnancy, diabetes mellitus, Cushing's disease, acromegaly, hypogonadism, reflex sympathetic Neurodystrophic syndromes, regional osteoporosis, osteomalacia, bone loss associated with joint replacement, HIV-related bone loss, bone loss associated with loss of growth hormone, bone loss associated with cystic fibrosis, fibrous dysplasia, chemotherapy-related bone loss, tumor-induced bone loss, cancer-related bone loss, hormonal ablative bone loss, multiple myeloma, anorexia nervosa, disease-related facial bone loss, disease-related skull bone loss, disease-related jaw bone loss, and disease-related skull bone loss. Other conditions involving aging-related bone loss include aging-related facial bone loss, aging-related skull bone loss, aging-related jaw bone loss, and aging-related skull bone loss.

[0117] In one embodiment, bone density or bone mineral density (BMD) can be measured to monitor bone loss or the efficacy of any treatment for bone loss.

[0118] As used herein, the term "bone density" or "bone mineral density" or "BMD" refers to the amount of bone mineral in bone tissue. Bone density measurements can be used in clinical medicine as an indirect indicator of osteoporosis and fracture risk. BMD test results can be reported in three different terms: 1) in g cm -2 Measured areal density; 2) Z score: the number of standard deviations above or below the mean for the patient's age, sex, and race; or 3) T score: the number of standard deviations above or below the mean for healthy 30-year-old adults of the same sex and race as the patient. Many non-invasive tests can be used to measure BMD. Exemplary tests may include: dual-energy X-ray absorptiometry (DXA or DEXA); dual X-ray absorptiometry and laser (DXL); quantitative computed tomography (QCT); quantitative ultrasound (QUS); single photon absorptiometry (SPA); dual photon absorptiometry (DPA); digital X-ray dosimetry (DXR); and single energy X-ray absorptiometry (SEXA). DXA is currently the most widely used, but quantitative ultrasound (QUS) has been described as a more cost-effective method for measuring bone density.

[0119] The terms "bone mineralization" and "bone mass accumulation" are used interchangeably in this application. Therefore, they should be considered synonyms in the specification or claims. "Bone mineralization" should also be considered synonymous with increasing, enhancing or improving "bone strength", "bone mineral density", "bone mineral content", "bone mass", "bone accumulation", etc.

[0120] As used herein, the term "autophagy-inducing agent," "autophagy-inducer," or "autophagy enhancer" refers to any agent or compound that can increase or stimulate autophagy in a cell by any pathway.

[0121] As used herein, the term "anabolic amino acid" refers to an amino acid that does not induce autophagy in the compositions of the present invention. Non-limiting examples of suitable anabolic amino acids may include leucine, isoleucine, arginine, glutamine, citrulline, and mixtures thereof. Preferably, the anabolic amino acid may include leucine and isoleucine.

[0122] As used herein, the term "branched chain amino acids" or "BCAAs" refers to a group of three essential amino acids: leucine, isoleucine, and valine.

[0123] As used herein, the term "precursor" refers to a compound or substance (or compounds or substances) that can produce an autophagy inducer.

[0124] The terms "food", "food product" and "food composition" mean a product or composition that is intended for ingestion by an individual (such as a human) and that provides at least one nutrient to the individual. The compositions of the present disclosure (including the various embodiments described herein) may comprise, consist of, or consist essentially of the following elements: the essential elements and limitations described herein, as well as any other or optional ingredients, components, or limitations described herein or that may be used in a diet.

[0125] As used herein, "complete nutrition" includes a comprehensive variety of macronutrients (protein, fat and carbohydrates) and micronutrients in sufficient amounts to be sufficient as the sole source of nutrition for the animal to which the composition is administered. From such complete nutritional compositions, an individual can obtain 100% of his nutritional requirements.

[0126] As used herein, the term "critically ill patient" is an individual experiencing an acute life-threatening episode or diagnosed as being at imminent risk of such an episode. A critically ill patient is medically unstable and is likely to die (eg, >50% chance of death) without treatment.

[0127] Non-limiting examples of critically ill patients include patients who have or are at risk for sustained acute life-threatening single or multiple organ system failure due to illness or injury, patients undergoing surgery and subsequently developing complications, and subjects who have undergone major organ surgery within the last week or have undergone major surgery within the last week.

[0128] More specific non-limiting examples of critically ill patients include patients who have or are at risk of sustained acute life-threatening single or multiple organ system failure due to illness or injury, and patients who are undergoing surgery and subsequently develop complications. Additional specific non-limiting examples of critically ill patients include: patients in need of one or more of cardiac surgery, brain surgery, chest surgery, abdominal surgery, vascular surgery, or transplantation; and patients suffering from one or more of the following: neurological disease, brain trauma, respiratory insufficiency, abdominal peritonitis, multiple trauma, severe burns, or critical illness polyneuropathy.

[0129] The term "intensive care unit" (ICU) means the part of a hospital where critically ill patients are treated. The term "intensive care unit" also covers: a nursing home; a clinic, such as a private practice; or a similar location where treatment activities that are the same or similar to those in an ICU are performed. The term "critically ill patient" covers an "ICU patient".

[0130] The term "multiple organ dysfunction" refers to a condition caused by infection, hypoperfusion, hypermetabolism or injury such as an accident or surgery. "Multiple organ failure" leading to death in critically ill patients is considered to be a descriptive clinical syndrome defined by dysfunction or failure of at least two important organ systems. The important organ systems that are consistently and most specifically affected are the liver, kidneys, lungs, as well as the cardiovascular, nervous and hematological systems. Non-limiting examples of multiple organ dysfunction include acute respiratory distress syndrome, heart failure, liver failure, renal failure, respiratory insufficiency, intensive care, shock, extensive burns, sepsis (e.g., systemic inflammatory response syndrome) and stroke.

[0131] The term "enteral administration" encompasses oral administration (including administration by gavage) as well as rectal administration, but oral administration is preferred. The term "parenteral administration" refers to delivery of a given substance by a route other than the digestive tract, and encompasses a variety of administration routes, such as intravenous, intraarterial, intramuscular, intracerebroventricular, intraosseous, intradermal, intrathecal, and intraperitoneal administration, intravesical infusion, and intracavernosal injection.

[0132] Preferred parenteral administration is intravenous administration. A specific form of parenteral administration is delivery by intravenous administration of nutrients. When food is not provided by other routes, parenteral nutrition is "total parenteral nutrition". "Parenteral nutrition" is preferably an isotonic or hypertonic aqueous solution (or a solid composition to be dissolved or a liquid concentrate to be diluted to obtain an isotonic or hypertonic solution), which contains sugars such as glucose and also contains one or more of lipids, amino acids and vitamins.

[0133] Implementation

[0134] One aspect of the present disclosure is a method for preventing or treating bone loss in an individual in need, enhancing or improving bone mineralization in an individual in need, enhancing or improving bone strength in an individual in need, enhancing or improving bone mineral density in an individual in need, and / or enhancing or improving bone mineral density in an individual in need. The method includes administering to an individual a composition comprising one or more anabolic amino acids, the composition further comprising one or more autophagy inducers, the amount of which effectively makes the composition at least neutral for autophagy and preferably positive for autophagy, such as in bone. The composition can be administered parenterally, enterally, or intravenously.

[0135] As used herein, "enhancing musculoskeletal effect" means that (i) the positive (anabolic) effect of one or more anabolic amino acids is greater than when one or more autophagy inducing compounds are not present at all or are present in a lower amount in an otherwise identically formulated composition, and / or (ii) the positive (anabolic) effect of one or more anabolic amino acids persists longer than when one or more autophagy inducing compounds are not present at all or are present in a lower amount in an otherwise identically formulated composition.

[0136] Non-limiting examples of suitable anabolic amino acids include leucine, isoleucine, arginine, glutamine, citrulline and mixtures thereof. The composition may comprise one or more of leucine, isoleucine or arginine in free form and / or bound as a peptide and / or protein (such as milk protein, animal protein or plant protein). Preferably, any leucine or arginine is present in the composition in an amount effective to activate mTOR. The daily dose of the composition may include one or more of the following: 0.175 mg / kg bw leucine to 142.85 mg / kg bw leucine, preferably 0.35 mg / kg bw leucine to 71.425 mg / kg bw leucine; 0.175 mg / kg bw to 71.425 mg / kg bw isoleucine; 20 mg / kg bw arginine to 300 mg / kg bw arginine, preferably 50 mg / kg bw arginine to 200 mg / kg bw arginine, and / or 20 mg / kg bw citrulline to 300 mg / kg bw citrulline, preferably 100 mg / kg bw citrulline to 200 mg / kg bw citrulline. The daily dose of one or more anabolic amino acids may be provided by one or more servings of the composition per day.

[0137] Non-limiting examples of suitable autophagy inducing compounds include thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts or ketone ester derivatives), 4,4'-dimethoxychalcone, and mixtures thereof. Non-limiting examples of suitable forms of spermidine include spermidine trihydrochloride, spermidine phosphate hexahydrate, spermidine phosphate hexahydrate, and L-arginyl-3,4-spermidine.

[0138] The composition comprises one or more autophagy inducing compounds in amounts effective to render the composition at least neutral with respect to autophagy and preferably positive with respect to autophagy, notwithstanding any negative effects of the one or more anabolic amino acids on autophagy.

[0139] The composition may include a pharmacologically effective amount of an autophagy inducer in a pharmaceutically suitable carrier. In an aqueous liquid composition, the concentration is preferably in the range of about 0.05% to about 4% by weight, or about 0.5% to about 2% by weight, or about 1.0% to about 1.5% by weight of the aqueous liquid composition.

[0140] In a specific embodiment, the method is to increase the plasma autophagy inducer level in the individual to, for example, 50 nmol / L plasma to 6000 nmol / L plasma, preferably 100 nmol / L plasma to 6000 nmol / L plasma. The method may include daily administration of an autophagy inducer in a weight range of 0.05 mg / kg body weight to 1 g / kg body weight, preferably 1 mg / kg body weight to 200 mg / kg body weight, more preferably 5 mg / kg body weight to 150 mg / kg body weight, even more preferably 10 mg / kg body weight to 120 mg / kg body weight, or most preferably 40 mg / kg body weight to 80 mg / kg body weight.

[0141] Typically, between 50 μg and 10 g of the autophagy inducer is administered to the individual in one or more portions per day.

[0142] Thymol (10% to 64%) is one of the main components of thyme (Thymus vulgaris L., Lamiaceae) essential oil. Carvacrol is present in pysarum (oregano) essential oil, thyme oil, oil obtained from pepper grass and wild bergamot. The essential oil of thyme subspecies contains between 5% and 75% carvacrol, while the savory (scented) subspecies has a content between 1% and 45%. Marjoram (origanum) and white moss oregano are rich in carvacrol, containing 50% and 60% to 80% respectively. Therefore, some embodiments of the composition include such plants and / or enriched plant extracts, essential oils or fractions, which provide at least a portion of thymol and / or carvacrol in the composition, specifically from thyme and oregano.

[0143] Malt extract is rich in spermidine. Accordingly, some embodiments of the composition comprise malt extract and / or an enriched malt extract providing at least a portion of the autophagy inducer in the composition.

[0144] Whey protein is rich in BCAAs, such as leucine and isoleucine. Accordingly, some embodiments of the composition comprise whey protein providing at least a portion of the anabolic amino acids in the composition.

[0145] The composition can induce autophagy in muscle, such as skeletal muscle. Non-limiting examples of such muscles include one or more of the vastus lateralis, gastrocnemius, tibialis, soleus, extensor digitorum longus (EDL), biceps femoris, semitendinosus, semimembranosus, gluteus maximus, extraocular muscles, facial muscles, or diaphragm.

[0146] The individual in need of inducing autophagy may be an elderly individual, such as an elderly animal or an elderly human. In some embodiments, the individual in need of inducing autophagy is an elderly animal or an elderly human.

[0147] The composition can induce autophagy in bone. For example, the inventors surprisingly found that the composition of the present invention can prevent or treat bone loss in an individual in need, enhance or improve bone mineralization in an individual in need, enhance or improve bone strength in an individual in need, enhance or improve bone mineral density in an individual in need, and / or enhance or improve bone mineral density in an individual in need.

[0148] For example, Figure 6b and the Examples demonstrate the synergistic effect of the composition of the present invention in improving or enhancing bone strength and bone mineral density in a subject. Figure 6b and the Examples demonstrate the significant effect of the composition of the present invention in improving or enhancing bone strength and bone mineral density in a subject.

[0149] In some embodiments, the individual in need of inducing autophagy has at least one bone-related disorder selected from: osteoporosis, osteomalacia (adults), conditions of low bone mineral density or quality (such as growth and development in children), osteitis fibrosa cystica, Paget's disease of bone, pyramidal (turtle) disease, and renal osteodystrophy.

[0150] In some embodiments, the individual in need of inducing autophagy suffers from bone loss due to a condition in which bone turnover is abnormally increased, for example, due to osteoporosis (including postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and juvenile osteoporosis); osteopenia; hormonal deficiency (vitamin D deficiency, tnalc, and female hypogonadism); hormonal excess (hyperprolactinemia, excess glucocorticoids, hyperthyroidism, hyperparathyroidism); nutritional factors (digestive disorders, malabsorption syndromes); Paget's disease; other forms of bone loss due to drug therapy; osteoarthritis; renal bone disease; inflammatory disorders (Crohn's disease, rheumatoid arthritis); immobility; space travel; osteoporosis caused by tumor bone marrow disorders; osteogenesis imperfecta; hypoalkaline phosphatasia; osteoporosis after hormone replacement therapy and genetic disorders and inborn errors of metabolism that lead to bone brittleness (familial hypoalkaline phosphatasia, Gaucher's disease, osteogenesis imperfecta, collagen disorders).

[0151] Individuals in need of inducing autophagy may be critically ill patients. In various embodiments, the method: can treat or prevent multiple organ dysfunction in critically ill patients, for example, if the patient has failed or disturbed homeostasis due to receiving parenteral nutrition; can protect critically ill patients from the effects of multiple organ dysfunction; can treat or prevent the development of lactic acidosis, such as lactic acidosis induced by parenteral nutrition; can treat or prevent muscle weakness in critically ill patients; can reduce or prevent morbidity or mortality exacerbated by parenteral nutrition; and / or can prevent body system collapse.

[0152] In some embodiments, the critically ill patient has at least one life-threatening condition selected from the following: lactic acidosis, myasthenia, hyperglycemia, multiple organ failure, homeostasis failure and homeostasis disorder. In one embodiment, the critically ill patient suffers from bone disease or bone-related disorders. In one embodiment, the critically ill patient suffers from a bone disease or bone-related disorder selected from the following: osteoporosis, osteomalacia (adult), low bone mineral density or quality (such as children's growth and development), osteitis fibrosa cystica, Paget's disease of bone, pyramid (tortoise) disease and renal osteodystrophy. In one embodiment, the critically ill patient suffers from non-infectious disorders. In one embodiment, the critically ill patient suffers from multiple organ dysfunction that is not caused by sepsis or is not related to sepsis. Multiple organ dysfunction and myasthenia are common in critical care environments and can be caused or aggravated by unbalanced parenteral nutrient delivery or relative or absolute nutrient overload delivered parenterally.

[0153] In some embodiments, the critically ill patient suffers from at least one disorder selected from the group consisting of severe trauma, multiple trauma, high-risk surgery, extensive surgery, brain trauma, cerebral hemorrhage, respiratory insufficiency, abdominal peritonitis, acute kidney injury, acute liver injury, severe burns, critical illness polyneuropathy, critical illness myopathy, and ICU-acquired muscle weakness.

[0154] In some embodiments, the critically ill patient is receiving enteral or parenteral nutrition.In some embodiments, the composition treats or prevents mitochondrial dysfunction, such as mitochondrial dysfunction induced by insufficient or unbalanced parenteral nutrition for the critically ill patient.

[0155] In another aspect of the present disclosure, a method overcomes one or more negative effects of one or more anabolic amino acids by preventing the degenerative process associated with autophagy loss. The method includes administering to an individual a composition comprising one or more anabolic amino acids, the composition also comprising one or more autophagy inducing compounds, such as thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B or D), rapamycin, Torin1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5'AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts or ketone ester derivatives), 4,4'-dimethoxychalcone and mixtures thereof, the amount of these autophagy inducing compounds effectively making the composition at least neutral for autophagy and preferably positive for autophagy, for example, in bone.

[0156] As used herein, the term "protein" includes amino acids in free form, molecules between 2 and 20 amino acids (referred to herein as "peptides"), and also includes longer amino acid chains. Small peptides (i.e., chains of 2 to 10 amino acids) are suitable for use in the composition alone or in combination with other proteins. The "free form" of an amino acid is the monomeric form of the amino acid. Suitable amino acids include both natural amino acids and unnatural amino acids. The composition may contain a mixture of one or more types of proteins, such as one or more of (i) peptides, (ii) longer amino acid chains, or (iii) free amino acids; and the mixture is preferably formulated to achieve a desired amino acid distribution / content.

[0157] The composition may comprise a protein providing at least a portion of one or more anabolic amino acids and / or at least a portion of one or more autophagy inducing compounds, and at least a portion of the protein may be from an animal source or a plant source, such as a milk protein, such as one or more of milk proteins, such as milk protein concentrate or milk protein isolate; caseinate or casein, such as micellar casein concentrate or micellar casein isolate; or whey protein, such as whey protein concentrate or whey protein isolate. In addition or alternatively, at least a portion of the protein may be a plant protein, such as one or more of soy protein or pea protein.

[0158] Mixtures of these proteins are also suitable, such as mixtures in which casein is a major but not all portion of the protein, mixtures in which whey protein is a major but not all portion of the protein, mixtures in which pea protein is a major but not all portion of the protein, and mixtures in which soy protein is a major but not all portion of the protein. In one embodiment, at least 10% by weight of the protein is whey protein, preferably at least 20% by weight, and more preferably at least 30% by weight. In one embodiment, at least 10% by weight of the protein is casein, preferably at least 20% by weight, and more preferably at least 30% by weight. In one embodiment, at least 10% by weight of the protein is plant protein, preferably at least 20% by weight, and more preferably at least 30% by weight.

[0159] The whey protein can be any whey protein, for example selected from whey protein concentrate, whey protein isolate, whey protein micelles, whey protein hydrolysate, acid whey, sweet whey, modified sweet whey (sweet whey from which casein-glycomacropeptide has been removed), fractions of whey protein, and any combination thereof.

[0160] The casein may be obtained from any mammal, but is preferably obtained from bovine milk, and is preferably micellar casein.

[0161] The protein can be unhydrolyzed, partially hydrolyzed (i.e., peptides having a molecular weight of 3 kDa to 10 kDa and an average molecular weight of less than 5 kDa), or fully hydrolyzed (i.e., wherein 90% of the peptides have a molecular weight of less than 3 kDa), for example, in the range of 5% to 95% hydrolysis. In some embodiments, the distribution of peptides of the hydrolyzed protein can be in a range of different molecular weights. For example, the majority (>50 mole percent or>50 weight %) of the peptides can have a molecular weight within 1 kDa to 5 kDa, or 5 kDa to 10 kDa, or 10 kDa to 20 kDa.

[0162] In one embodiment, the composition comprises a carbohydrate source. Any suitable carbohydrate can be used in the composition, including but not limited to starch (e.g., modified starch, amylose, tapioca starch, corn starch), sucrose, lactose, glucose, fructose, corn syrup solids, maltodextrin, xylitol, sorbitol, or a combination thereof.

[0163] The carbohydrate source preferably is no more than 50 energy % of the composition, more preferably no more than 36 energy % of the composition, and most preferably no more than 30 energy % of the composition.

[0164] In one embodiment, the composition comprises a fat source. The fat source may include any suitable fat or fat mixture. Non-limiting examples of suitable fat sources include vegetable fats (such as olive oil, corn oil, sunflower oil, high oleic sunflower oil, rapeseed oil, canola oil, hazelnut oil, soybean oil, palm oil, coconut oil, black currant seed oil, borage oil, lecithin, etc.), animal fats (such as milk fat); or combinations thereof.

[0165] The composition can be administered to an individual, such as a human, e.g., an elderly individual or a critically ill individual, at a therapeutically effective dose. The therapeutically effective dose can be determined by one skilled in the art and will depend on many factors known to those skilled in the art, such as the severity of the disorder and the weight and general condition of the individual.

[0166] The composition is preferably administered to an individual at least two days per week, more preferably at least three days per week, and most preferably all seven days per week; for at least one week, at least one month, at least two months, at least three months, at least six months, or even longer. In some embodiments, the composition is administered to an individual for multiple consecutive days, for example, at least until a therapeutic effect is achieved. In one embodiment, the composition can be administered to an individual daily for at least 30 consecutive days, 60 days, or 90 days.

[0167] The above application examples do not require continuous daily application without interruption. Instead, there may be some brief interruptions in the application, such as two to four days of interruption during the application. The ideal duration of application of the composition can be determined by those skilled in the art.

[0168] In a preferred embodiment, the composition is administered to the individual orally or enterally (eg, by tube feeding).For example, the composition can be administered to the individual in the form of a beverage, capsule, tablet, powder or suspension.

[0169] The composition can be any kind of composition suitable for human and / or animal consumption. For example, the composition can be selected from food compositions, dietary supplements, nutritional compositions, nutrition, powdered nutritional products reconstituted with water or milk before consumption, food additives, medicines, beverages and drinks. In one embodiment, the composition is an oral nutritional supplement (ONS), a complete nutritional formula, a medicine, a medical product or a food product. In a preferred embodiment, the composition is administered to an individual in the form of a beverage. The composition can be stored in a pouch in powder form and then suspended in a liquid such as water for use.

[0170] In some cases where oral or enteral administration is not possible or advisable, the compositions may also be administered parenterally.

[0171] In some embodiments, the composition is administered to an individual in a single dosage form, i.e., all compounds are present in one product that is provided to the individual in combination with a diet. In other embodiments, the composition is co-administered in separate dosage forms, e.g., at least one component is separated from one or more of the other components of the composition.

[0172] Example

[0173] The following non-limiting examples present scientific data that develop and support the concept of administering a composition comprising one or more anabolic amino acids that also comprises one or more autophagy inducers and / or one or more autophagy inducing amino acids in amounts effective to render the composition at least neutral with respect to autophagy and preferably positive with respect to autophagy, thereby inducing autophagy in an individual in need thereof, notwithstanding any negative effects of the one or more anabolic amino acids on autophagy.

[0174] Example 1

[0175] Experimental protocol

[0176] Zebrafish autophagy reporter genes are generated by stable expression of LC3 proteins fused to ZsGreen under the control of skeletal muscle-specific promoters. Larvae from outbred transgenic zebrafish were raised at 28 ° C under standard laboratory conditions and treated in 96-well plates at 48 hours after fertilization, with the indicated amino acid concentration range of 0,25mM to 10mM (n=24). After 16 hours of treatment, the larvae were anesthetized with 0.016% tricaine and imaged with an ImageXpress confocal system (Molecular Devices) at 20 times magnification. Z stack images of each larva were captured, and maximum projection images were generated. LC3 dots were calculated using MetaXpress software (Molecular Devices) and normalized to fish area.

[0177] Figure 1 Figures 3 to 3 show the experimental results.

[0178] Example 2

[0179] Materials and methods

[0180] Aged mice are a good model for evaluating the effects of nutritional interventions on age-related decline. Using this model, it can be observed that, as in humans, muscle function declines with age. In this model, 20-month-old mice are fed a normal diet or the same diet supplemented with a specific amino acid mixture (AA) for 3 months (see Table 1). The AA mixture is dosed at 1.65 mg / kg body weight / day.

[0181] Table 1

[0182] Amino Acids % in the mixture Leucine 28,67 Isoleucine 14,29 Valine 14,29 Proline 12,21 Glycine 12,21 Lysine 14,84 Cysteine 3,48

[0183] To evaluate the effect of aging, adult mice (6 months old) were also fed a normal diet for 3 months. The age-related in vivo force frequency response loss was measured with a 305C muscle rod system. FIG. 4 shows the effect of a specific amino acid mixture (AA) on the force frequency response of elderly rats (old) and a comparison with adult mice fed a normal diet, which was significantly improved by AA supplementation, indicating improved muscle function.

[0184] Example 3

[0185] Evaluation of the long-term (3 months) effects of thymol (an exemplary autophagy inducer) and an amino acid mixture (referred to as an autophagy inducer), alone or in combination, on muscle function in aged mice.

[0186] As shown in Figure 5, young mice (24-26 weeks old; n = 12 / group; control) were fed a control diet with alanine for isonitrogenous. Old mice (78 weeks old; n = 12 / group; present invention) were fed: 1) thymol (Compound 1); 2) amino acid (AA) mixture and thymol (Compounds 2 and 1); or 3) AA mixture (Compound 2). In the experiments, thymol was given by gavage; the AA mixture was given in water; and alanine for isonitrogenous was given to young mice (adult mice) as a control. Untreated old mice were also used as another control (old untreated).

[0187] The AA mixture contained 28.67% leucine, 14.29% isoleucine, 14.29% valine, 12.21% proline, 12.21% glycine, 14.84% lysine and 3.48% cysteine ​​(see Table 1).

[0188] Figure 6a shows the unexpected results of the claimed invention in improving or enhancing bone mineral density (BMD) in a subject.

[0189] For example, as shown in Figure 6a, elderly untreated subjects exhibited much lower bone mineral density compared to adult controls fed alanine for isonitrogenation. Mice fed with thymol (Compound 1; Aged Thymol) unexpectedly exhibited increased bone mineral density compared to adult controls and elderly untreated controls. Specifically, mice fed with thymol (Compound 1; Aged Thymol) unexpectedly exhibited an increase in bone mineral density of 1.6% compared to elderly untreated controls.

[0190] As shown in Figure 6a, mice fed with the AA mixture (Compound 2; Aged AA) unexpectedly exhibited increased bone mineral density compared to adult controls and aged untreated controls. Specifically, mice fed with the AA mixture (Compound 2; Aged AA) unexpectedly exhibited an increase in bone mineral density of 0.8% compared to aged untreated controls.

[0191] In addition, as shown in Figure 6a, compared with adult controls and elderly untreated controls, mice fed with both amino acid (AA) mixtures and thymol (compounds 2 and 1) unexpectedly showed a higher level of increase in bone mineral density. Specifically, compared with elderly untreated controls, mice fed with both amino acid (AA) mixtures and thymol (compounds 2 and 1) showed an increase in bone mineral density of 2.5%.

[0192] Thus, the exemplary combination of the amino acid (AA) mixture and thymol of the claimed invention exhibits an additive effect of both the amino acid (AA) mixture and thymol on bone mineral density.

[0193] Figure 6b shows the unexpected results of the synergistic effect of the claimed invention in improving or enhancing bone strength and bone mineral density in a subject.

[0194] For example, as shown in Figure 6b, elderly untreated subjects (Aged Untreated) exhibited much lower bone stiffness compared to adult controls (Adult) fed isonitrogenous alanine.

[0195] As further shown in Figure 6b, mice fed with thymol (aged thymol) unexpectedly exhibited increased bone stiffness compared to aged untreated controls (aged untreated). Specifically, mice fed with thymol (Compound 1; Aged thymol) unexpectedly exhibited a 12% increase in bone stiffness compared to aged untreated controls (aged untreated).

[0196] In contrast, mice fed with the AA mixture (Compound 2; Old AA) did show an increase in bone stiffness compared to aged untreated controls (Aged Untreated).

[0197] Unexpectedly, as shown in Figure 6b, compared with adult controls (Adult) and elderly untreated subjects (Old Untreated), mice fed with both amino acid (AA) mixture and thymol (Compounds 2 and 1) showed a much higher level of bone hardness increase. Specifically, compared with elderly untreated controls (Old Untreated), mice fed with both amino acid (AA) mixture and thymol (Compounds 2 and 1) showed a 20% increase in bone hardness.

[0198] Therefore, the experimental results in Figure 6b indicate the synergistic effect of the amino acid (AA) mixture and thymol (compounds 2 and 1).

[0199] It should be understood that various changes and modifications made to the presently preferred embodiments described herein will be apparent to those skilled in the art. These changes and modifications may be made without departing from the spirit and scope of the subject matter of the present invention and without diminishing its intended advantages. Therefore, such changes and modifications are intended to be covered by the appended claims.

Claims

1. A method of improving and / or enhancing at least one of bone mineralization, bone strength, bone mass and bone mineral density in an individual in need thereof, the method comprising administering to the individual a composition comprising one or more anabolic amino acids, and the composition further comprising one or more autophagy inducing compounds.

2. The method of claim 1, wherein the one or more autophagy inducing compounds are selected from thymol, carvacrol, spermidine, urolithin (e.g., urolithin A, B or D), rapamycin, Torin 1, valproic acid, polyphenols (e.g., resveratrol), caffeine, metformin, 5' AMP-activated protein kinase (AMPK) activators, L-type calcium channel inhibitors, ketones (e.g., β-hydroxybutyrate, ketone salts or ketone ester derivatives), 4,4'-dimethoxychalcone, and mixtures thereof.

3. The method of claim 1, wherein the one or more anabolic amino acids are selected from the group consisting of leucine, isoleucine, arginine, glutamine, citrulline, and mixtures thereof.

4. The method of claim 1, wherein the one or more anabolic amino acids are selected from the group consisting of leucine, isoleucine, arginine, glutamine, citrulline, and mixtures thereof.

5. The method of claim 1, wherein the anabolic amino acid is selected from the group consisting of leucine, arginine, glutamine, and mixtures thereof, and the composition is administered in an amount effective to activate mTOR in the individual.

6. The method of claim 1, wherein the composition is administered in an amount effective to induce autophagy in bone.

7. The method of claim 1, wherein the individual is an elderly individual.

8. The method of claim 1, wherein the individual suffers from a bone disease.

9. The method of claim 1, wherein the individual suffers from a condition selected from the group consisting of osteoporosis, osteomalacia, rickets, osteitis fibrosa cystica, Paget's disease of bone, pyramidal disease, and combinations thereof.

10. The method of claim 1, wherein the composition comprises a protein that provides at least a portion of the anabolic amino acids and / or at least a portion of the autophagy inducing compound, wherein at least a portion of the protein is selected from the group consisting of a protein from an animal source, a protein from a plant source, and a mixture thereof.

11. The method of claim 1, wherein the composition comprises a protein selected from the group consisting of milk protein, whey protein, caseinate, micellar casein, pea protein, soy protein, and mixtures thereof.

12. The method of claim 1, wherein the composition comprises a component selected from the group consisting of amino acids in free form, unhydrolyzed proteins, partially hydrolyzed proteins, fully hydrolyzed proteins, and mixtures thereof.

13. The method of claim 12, wherein at least a portion of the protein is hydrolyzed.

14. The method of claim 1, wherein the composition comprises at least partially hydrolyzed proteins comprising peptides having 2 to 10 amino acids.

15. The composition of claim 12, wherein the protein has a formula selected from the group consisting of: (i) at least 50% of the protein has a molecular weight of 1 kDa to 5 kDa, (ii) at least 50% of the protein has a molecular weight of 5 kDa to 10 kDa, and (iii) at least 50% of the protein has a molecular weight of 10 kDa to 20 kDa.

16. The method of claim 1, wherein the composition further comprises a carbohydrate source and / or a fat source.

17. The method of claim 1, wherein the composition is administered by at least one route selected from oral, enteral, parenteral, and intravenous injection.

18. The method of claim 1, wherein the composition comprises an amount of the anabolic amino acid that is about equal to or greater than the amount of the anabolic amino acid.

19. The method of claim 1, wherein the one or more autophagy inducing compounds comprise one or more autophagy inducing amino acids or their precursors.

20. The method of claim 19, wherein the one or more autophagy-inducing amino acids are selected from the group consisting of glycine, cysteine, proline, glutamic acid, valine, tyrosine, precursors thereof, and mixtures thereof.

Citation Information

Cited By

  • Application of BCKDK inhibitor in preparation of medicine for preventing and treating osteoporosis

    CN121731475A